Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
GRAIL, LLC (GRAL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/29/2025: GRAL (5-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Outstanding Performance
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $40.5
1 Year Target Price $40.5
| 1 | Strong Buy |
| 0 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 72.76% | Avg. Invested days 39 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  5.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 07/29/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.38B USD | Price to earnings Ratio - | 1Y Target Price 40.5 |
Price to earnings Ratio - | 1Y Target Price 40.5 | ||
Volume (30-day avg) 4 | Beta - | 52 Weeks Range 12.33 - 63.99 | Updated Date 07/29/2025 |
52 Weeks Range 12.33 - 63.99 | Updated Date 07/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -59.59 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -482.59% |
Management Effectiveness
Return on Assets (TTM) -11.98% | Return on Equity (TTM) -62.22% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 766439615 | Price to Sales(TTM) 10.53 |
Enterprise Value 766439615 | Price to Sales(TTM) 10.53 | ||
Enterprise Value to Revenue 5.86 | Enterprise Value to EBITDA - | Shares Outstanding 35973500 | Shares Floating 24099363 |
Shares Outstanding 35973500 | Shares Floating 24099363 | ||
Percent Insiders 13.86 | Percent Institutions 67.04 |
Upturn AI SWOT
GRAIL, LLC
Company Overview
History and Background
GRAIL, LLC was founded in 2016 by Illumina, Inc. to develop early cancer detection tests using next-generation sequencing. It aimed to detect cancer signals in blood samples at early stages, before symptoms appear. After initially being spun off from Illumina, it was later re-acquired by Illumina.
Core Business Areas
- Early Cancer Detection: GRAIL focuses on developing and commercializing multi-cancer early detection (MCED) tests. These tests analyze circulating cell-free DNA in blood to detect cancer signals from multiple cancer types.
- Clinical Research and Development: The company invests heavily in clinical trials and research to validate the performance and clinical utility of its cancer detection technology.
Leadership and Structure
Following its re-acquisition, GRAIL operates as a division within Illumina. The leadership structure involves executives overseeing the GRAIL division and reporting to Illumina's broader leadership team.
Top Products and Market Share
Key Offerings
- Galleri: Galleri is GRAIL's flagship MCED test, designed to detect a common cancer signal across more than 50 cancer types. Market share data is evolving with adoption. Competition includes single cancer detection tests and other MCED approaches from companies like Exact Sciences (EXAS) and Freenome. Revenue from Galleri is growing but not yet consistently profitable.
Market Dynamics
Industry Overview
The industry for early cancer detection is rapidly growing, driven by advancements in genomics and a desire for earlier intervention. The field is characterized by intense research and development and competition among multiple players.
Positioning
GRAIL is positioned as a leader in MCED technology, leveraging its expertise in next-generation sequencing and large-scale clinical studies. Its competitive advantages include its comprehensive approach to detecting multiple cancers and its established brand recognition.
Total Addressable Market (TAM)
The estimated TAM for MCED is tens of billions of dollars. GRAIL is positioned to capture a significant portion of this market with Galleri.
Upturn SWOT Analysis
Strengths
- Pioneering MCED technology
- Strong intellectual property portfolio
- Large-scale clinical trial data
- Established brand recognition (though associated with uncertainty)
- Access to Illumina's resources post-acquisition
Weaknesses
- High cost of goods sold
- Uncertainty regarding regulatory approval pathways
- Need for further clinical validation to demonstrate long-term benefits
- Ethical concerns surrounding widespread early detection
Opportunities
- Expansion of MCED testing to new populations
- Integration of MCED testing into routine clinical care
- Development of personalized cancer screening strategies
- Partnerships with healthcare providers and payers
Threats
- Regulatory hurdles and delays
- Competition from other MCED developers
- Challenges in demonstrating clinical utility and cost-effectiveness
- Negative publicity or safety concerns
- Reimbursement challenges
Competitors and Market Share
Key Competitors
- EXAS
- GH
- NVTA
Competitive Landscape
GRAIL's advantage lies in its established technology and access to Illumina's resources. Disadvantages include regulatory hurdles and the need to demonstrate cost-effectiveness compared to existing screening methods.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is tied to the development and commercialization of Galleri. Adoption rates have been slower than initially projected.
Future Projections: Future growth is dependent on regulatory approvals, reimbursement coverage, and clinical adoption of Galleri. Analyst estimates vary depending on these factors.
Recent Initiatives: Recent initiatives include expanding clinical trials, pursuing regulatory approvals, and partnering with healthcare providers to offer Galleri.
Summary
GRAIL, now within Illumina, possesses cutting-edge early cancer detection technology but faces regulatory and commercialization challenges. Galleri holds enormous potential, but its success hinges on proven clinical utility and broad adoption. Current growth is slower than anticipated. The high costs of developing and marketing Galleri put a strain on the overall financial performance of Illumina.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings (Illumina)
- Analyst Reports
- Industry News and Publications
Disclaimers:
This analysis is based on publicly available information and analyst estimates. Actual results may vary. This is not investment advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About GRAIL, LLC
Exchange NASDAQ | Headquaters Menlo Park, CA, United States | ||
IPO Launch date 2024-06-25 | CEO & Director Mr. Robert P. Ragusa | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 1000 | Website https://grail.com |
Full time employees 1000 | Website https://grail.com | ||
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, it develops minimal residual disease post-diagnostic tests. The company was incorporated in 2015 and is headquartered in Menlo Park, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.